Experimental Roche pill cuts MS relapses by more than half in big studies
Published
In two late-stage trials, Roche's fenebrutinib lowered the yearly relapse rate in relapsing multiple sclerosis by 55% compared with teriflunomide, an existing MS pill, over about two years. It is still experimental and not yet approved by FDA.
Source: Roche
This is a plain-language summary. Read the original source for full details.